Please assess the completion status of the following clinical trial:

Trial Title: hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Primary islet allotransplant~2. Type 1 diabetes mellitus, complicated by at least one of the following situations that persist despite intensive efforts in close cooperation with their diabetes care team:~   1. Metabolic lability/instability;~  2. Reduced awareness of hypoglycemia;~  3. Persistently poor glucose control (as defined by HgbA1c\>10% at the end of six months of intensive management efforts with the diabetes care team);~  4. Progressive secondary complications.~3. Age 18 and older~4. Able to give written informed consent~Exclusion Criteria:~1. Age less than 18 years~2. Body weight greater than75 kg.~3. BMI greater than 26 kg/m2 for male and females~4. Waist-to-hip ratio 0.80 (female) and 0.95 (male)~5. First degree relative with type 2 diabetes~6. Insulin requirement of greater than 0.7 IU/kg/day~7. HbA1C greater than 12%~8. Positive C-peptide response to intravenous arginine stimulation~9. Untreated proliferative retinopathy~10. Macroalbuminuria (urinary albumin excretion greater than 300 mg/24hrs)~11. Creatinine clearance greater than 85 ml/min/1.73 m2 in females, greater than 95 ml/min/1.73 m2 in males~12. Serum creatinine greater than 1.2 mg/dl~13. Previous pancreas or islet transplant~14. Previous OKT3 antibody therapy~15. Presence of history of panel-reactive anti-HLA antibodies greater than 10%~16. Abnormal T4 and TSH despite thyroid replacement therapy~17. Positive pregnancy test, or presently breast-feeding~18. Active infection~19. Negative screen for Epstein-Barr Virus (EBV) by an EBNA method~20. Invasive aspergillus infection within year prior to study entry~21. Any history of malignancy~22. Active alcohol or substance abuse~23. History of non-adherence to prescribed regimens~24. Psychiatric disorder making the subject not a suitable candidate for transplantation~25. Karnofsky performance score greater than 70~26. Baseline Hgb greater than 11.7 g/dl; lymphopenia (greater than 1,000/L), or leukopenia (greater than 4,000 total leukocytes/L), or an absolute CD4+ count \<500/L~27. Thrombocytopenia greater than 150 x 109/L~28. Use of warfarin or other anticoagulant therapy (except aspirin) or patient with PT-INR greater than 1.5~29. Severe co-existing cardiac disease~30. Baseline liver function tests outside of normal range~31. Presence of gallstones on baseline ultrasound exam~32. Active peptic ulcer disease~33. Severe unremitting diarrhea or other gastrointestinal disorders potentially interfering with the ability to absorb oral medications~34. Celiac disease~35. Hyperlipidemia (fasting LDL cholesterol greater than 130 mg/dl, treated or untreated; and/or fasting triglycerides greater than 200 mg/dl)~36. Addison's disease.~37. Under treatment for a medical condition requiring chronic use of systemic steroids~38. Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).